Barclays’s Lisata Therapeutics LSTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-4
| Closed | -$10 | – | 5500 |
|
|
2025
Q3 | $10 | Hold |
4
| – | – | ﹤0.01% | 5397 |
|
|
2025
Q2 | $12 | Hold |
4
| – | – | ﹤0.01% | 5152 |
|
|
2025
Q1 | $9 | Hold |
4
| – | – | ﹤0.01% | 5181 |
|
|
2024
Q4 | $12 | Sell |
4
-3
| -43% | -$9 | ﹤0.01% | 5224 |
|
|
2024
Q3 | $21 | Buy |
7
+3
| +75% | +$9 | ﹤0.01% | 5231 |
|
|
2024
Q2 | $14 | Hold |
4
| – | – | ﹤0.01% | 4785 |
|
|
2024
Q1 | $12 | Hold |
4
| – | – | ﹤0.01% | 5025 |
|
|
2023
Q4 | $11 | Hold |
4
| – | – | ﹤0.01% | 5195 |
|
|
2023
Q3 | $9 | Sell |
4
-23
| -85% | -$64 | ﹤0.01% | 4569 |
|
|
2023
Q2 | $100 | Buy |
27
+21
| +350% | +$76 | ﹤0.01% | 4443 |
|
|
2023
Q1 | $19 | Buy |
6
+2
| +50% | +$7 | ﹤0.01% | 5028 |
|
|
2022
Q4 | $10 | Hold |
4
| – | – | ﹤0.01% | 5239 |
|
|
2022
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 4995 |
|
|
2022
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 5163 |
|
|
2022
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 5340 |
|
|
2021
Q4 | $0 | Sell |
4
-1,403
| -100% | -$21.7K | ﹤0.01% | 4499 |
|
|
2021
Q3 | $26K | Buy |
1,407
+992
| +239% | +$19.4K | ﹤0.01% | 4318 |
|
|
2021
Q2 | $10K | Buy |
415
+411
| +10,275% | +$9.74K | ﹤0.01% | 4638 |
|
|
2021
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 4986 |
|
|
2020
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 5066 |
|
|
2020
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 5416 |
|
|
2020
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 5969 |
|
|
2020
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 6334 |
|
|
2019
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 6617 |
|
|
2019
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 6952 |
|
|
2019
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 7104 |
|
|
2019
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 7193 |
|
|
2018
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 7151 |
|
|
2018
Q3 | $0 | Sell |
4
-40
| -91% | -$3.28K | ﹤0.01% | 7276 |
|
|
2018
Q2 | $4K | Buy |
44
+40
| +1,000% | +$2.82K | ﹤0.01% | 6742 |
|
|
2018
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 7210 |
|
|
2017
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 7021 |
|
|
2017
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 6959 |
|
|
2017
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 6798 |
|
|
2017
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 6880 |
|
|
2016
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 6733 |
|
|
2016
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 6713 |
|
|
2016
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 6486 |
|
|
2016
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 6306 |
|
|
2015
Q4 | $1K | Buy |
+4
| New | +$734 | ﹤0.01% | 5832 |
|
|
2015
Q3 | – | Sell |
-3
| Closed | – | – | 6951 |
|
|
2015
Q2 | $0 | Sell |
3
-2
| -40% | -$743 | ﹤0.01% | 7120 |
|
|
2015
Q1 | $1K | Sell |
5
-4
| -44% | -$2.17K | ﹤0.01% | 6974 |
|
|
2014
Q4 | $4K | Buy |
9
+7
| +350% | +$4.76K | ﹤0.01% | 7017 |
|
|
2014
Q3 | $1K | Sell |
2
-110
| -98% | -$96.3K | ﹤0.01% | 7510 |
|
|
2014
Q2 | $101K | Buy |
112
+78
| +229% | +$75.8K | ﹤0.01% | 5405 |
|
|
2014
Q1 | $36K | Buy |
34
+33
| +3,300% | +$35.8K | ﹤0.01% | 6251 |
|
|
2013
Q4 | $1K | Sell |
1
-72
| -99% | -$71.2K | ﹤0.01% | 7441 |
|
|
2013
Q3 | $88K | Buy |
+73
| New | +$81.1K | ﹤0.01% | 5709 |
|
Other funds holding LSTA
BCM
GSC
Barclays's LSTA Position: Q4 2025 in Review
Barclays sold out of Lisata Therapeutics (LSTA) in Q4 2025, closing a stake of 4 shares — an estimated $10 sold.
Barclays first reported a position in LSTA in Q3 2013 and held it in 48 quarters. The position peaked at $101K in Q2 2014. 25 funds tracked by Wall St. Rank hold LSTA as of Q4 2025.
- Barclays reported no remaining Lisata Therapeutics position as of Q4 2025 after selling out during the quarter.
- Barclays sold 4 Lisata Therapeutics shares in Q4 2025, an estimated $10.
- Barclays first reported a position in Lisata Therapeutics in Q3 2013 and held it in 48 quarters.
- Barclays's Lisata Therapeutics position peaked at $101K in Q2 2014.
- 25 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2025.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.